Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma.
Ret is a developmentally regulated tyrosine kinase involved in formation and maintenance of the nervous system. Ret mutations predisposing to pheochromocytomas and medullary thyroid carcinomas occur in multiple endocrine neoplasia (MEN) syndromes 2A and 2B. Biochemical studies have demonstrated overexpression of Ret mRNA and protein in pheochromocytomas compared to normal adrenal medulla. However, the cellular distribution of Ret in the normal human adrenal and in hyperplastic lesions that antecede pheochromocytomas are unclear. The present investigation was undertaken to resolve the histological distribution of Ret in the normal human adrenal, in pheochromocytomas evolving from adrenal medullary hyperplasia in MEN2A and in sporadic pheochromocytomas. Ret expression was studied by immunohistochemistry using both a polyclonal and a monoclonal antibody, with confirmation by immunoblotting of representative cases. Only occasional cells stained for Ret in the normal adrenal, consistent with the distribution in adult adrenals of other species. Heterogeneous, progressively increased Ret expression was observed during the evolution of pheochromocytomas. In both normal and neoplastic adrenal, the most intense immunoreactivity was observed in cells with neuron-like features. Our finding that Ret is not expressed at high levels in the early stages of disease suggests that elucidation of mechanisms that regulate Ret expression is required for understanding the pathobiology of MEN2A. The association of high-level Ret expression with neuronal morphology suggests that the variable overexpression of Ret in pheochromocytomas might in part be an epiphenomenon, reflecting the known phenotypic plasticity of these tumors.
Powers
James F
JF
Department of Pathology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA. jpowers1@tufts-nemc.org
Brachold
Jaime M
JM
Tischler
Arthur S
AS
D000310:Adrenal Gland Neoplasms / Q000737:chemistry* / Q000473:pathology; D000313:Adrenal Medulla / Q000737:chemistry* / Q000473:pathology*; D000328:Adult; D005260:Female; D018305:Ganglioneuroblastoma / Q000737:chemistry; D005729:Ganglioneuroma / Q000737:chemistry; D006801:Humans; D006965:Hyperplasia; D007150:Immunohistochemistry; D007163:Immunosorbent Techniques; D008297:Male; D008875:Middle Aged; D018813:Multiple Endocrine Neoplasia Type 2a / Q000737:chemistry; D018814:Multiple Endocrine Neoplasia Type 2b / Q000737:chemistry; D010673:Pheochromocytoma / Q000737:chemistry* / Q000473:pathology; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis*
D011518:Proto-Oncogene Proteins; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases